GSK to get USD 1.25 billion from Gilead Sciences to settle dispute of HIV based drug unit
Gilead will also pay a 3 percent royalty until 2027 on sales of Biktarvy and on future US sales of any product containing its main component.;
New Delhi: Britain's GlaxoSmithKline will receive $1.25 billion from Gilead Sciences as part of a settlement between its HIV medicines unit and the U.S.-based drugmaker, ending a long-drawn patent dispute.
The settlement, announced by GSK on Tuesday, relates to Gilead's antiretroviral drug Biktarvy, a medicine used to check the AIDS-causing virus, which GSK said in 2018 infringed on its unit ViiV Healthcare's dolutegravir and other similar compounds.
HIV medicines developed by ViiV, in which Pfizer and Japan's Shionogi also hold small stakes, are a major part of GSK's plan to support its lagging pharmaceuticals business as it readies to spin off its consumer healthcare arm.
The payment is expected to be made in the first quarter this year, London-listed GSK said. Gilead will also pay a 3% royalty until 2027 on sales of Biktarvy and on future U.S. sales of any product containing its main component.
Read also: Justify dose modification criteria for anti-cancer drug: Authority tells GSK
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.